Clinical trials: insulin glargine
Diabetes Mellitus, Type 2
A Study of LY3209590 in Participants With Type 2 Diabetes
This study will evaluate the safety and tolerability of LY3209590 when given by injection under the skin to participants with type 2 diabetes.
- Trial name
- NCT03367377
- Testing
- LY3209590, Insulin Glargine
- Where
- 3 sites in United States, Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous
Comparison of incidence of hypoglycaemic events and glycaemic fluctuations in diabetic patients with basal substitution with NPH insuline versus insuline glargine.
- Trial name
- NCT00322075
- Testing
- insulin glargine
- Where
- Czechia
- Volunteers
- 35 people
- Sponsor
- Sanofi
Type 2 Diabetes, Liver Cirrhosis
Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial
Liver disease is an important cause of death in type 2 diabetes. In the population-based Verona Diabetes Study cirrhosis was the fourth leading cause of death and accounted for 4.4% of diabetes-related deaths.
- Trial name
- VIRDICT (NCT01143948)
- Testing
- Glargine & Glulisine, Regular insulin, NPH & regular insulin
- Where
- Egypt
- Volunteers
- 45 people
- Sponsor
- Cairo University
Diabetes Mellitus
An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice
The objective of this survey on this registered product is to confirm the efficacy, and safety profile of Lantus in every day medical practice.
- Trial name
- NCT00576368
- Testing
- INSULIN GLARGINE
- Where
- Belgium
- Volunteers
- 4,464 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients
Primary Objective: The primary objective of this study is to obtain efficacy and safety descriptive data on 2 different titration algorithms: the INSIGHT titration algorithm (self-titration of 1 unit/day) and the EDITION trial…
- Trial name
- TITRATION (NCT02401243)
- Testing
- INSULIN GLARGINE (U300)
- Where
- 25 sites in Canada
- Volunteers
- 253 people
- Sponsor
- Sanofi
Gestational Diabetes Mellitus, Pregnancy in Diabetic
Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)
We propose a pragmatic, unblinded, randomized controlled, single center trial of 56 pregnant individuals with Gestational diabetes mellitus (GDM).
- Conditions
- Gestational Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy, High Risk
- Trial name
- NCT05922033
- Testing
- Patient-led Insulin (intervention group), Provider-led Insulin (standard care)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Ohio State University
Diabetes Mellitus, Type 2
A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine
This study will examine the influence of the basal insulins detemir and glargine on risk of cardiovascular death and death from all causes in patients treated by their general practitioner in United Kingdom (UK).
- Trial name
- NCT03960814
- Testing
- Insulin detemir
- Where
- Denmark
- Volunteers
- 12,847 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)
The purpose of this study is to assess the effect of the addition of sitagliptin (administered as MK-0431A or MK-0431A XR) relative to the addition of placebo on glycated hemoglobin (A1C), and the safety and tolerability of the…
- Trial name
- NCT01760447
- Testing
- Sitagliptin plus metformin, Metformin, Sitagliptin plus metformin XR
- Volunteers
- 223 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy
The purpose of this study is to evaluate the comparative efficacy of insulin pump therapy versus multiple daily injections in insulin-taking type 2 diabetes mellitus who are sub-optimally controlled with premixed insulin regimen.
- Trial name
- NCT03112538
- Testing
- Insulin Pump, Multiple daily injections of insulin
- Where
- Malaysia
- Volunteers
- 118 people
- Sponsor
- Clinical Research Centre, Malaysia
Diabetes Mellitus
Comparison of Insulin Therapy in Treating Post-Transplant Diabetes
To determine if the use of insulin isophane results in improved control of blood sugars compared to the use of insulin glargine in new onset diabetes after kidney, lung, or heart transplantation (NODAT).
- Trial name
- NCT01963728
- Testing
- Insulin, Isophane, insulin glargine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Inova Health Care Services
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg) with insulin glargine (IGlar) in patients with type 2 diabetes.
- Trial name
- BEGIN™ (NCT01006291)
- Testing
- insulin degludec, insulin glargine
- Where
- 72 sites in Argentina, Finland and 12 more
- Volunteers
- 687 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change.
- Trial name
- LixiLan-G (NCT02787551)
- Testing
- Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide
- Where
- 124 sites in United States, Canada and 7 more
- Volunteers
- 514 people
- Sponsor
- Sanofi
Type2 Diabetes Mellitus
Empagliflozin Effect on Glucose Toxicity
Empagliflozin effect on glucose toxicity in type 2 diabetes patients - a randomized, open-label, controlled, parallel group, exploratory study
- Trial name
- NCT03437330
- Testing
- Empagliflozin (Jardiance®), Insulin Glargine (Lantus®)
- Where
- 2 sites in Germany
- Sponsor
- University Hospital Tuebingen
Type 2 Diabetes
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine (mentioned as insulin glargine in this form) taken daily in people with type 2…
- Trial name
- COMBINE 4 (NCT06269107)
- Testing
- IcoSema, Insulin glargine
- Where
- 118 sites in United States, China and 8 more
- Volunteers
- 485 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)
To compare in terms of HbA1c insulin naive patients with Type 2 Diabetes starting with insulin glargine on an algorithm with insulin naive patients starting with insulin glargine on the physician's standard practice.
- Trial name
- Malbec (NCT00627471)
- Testing
- Insulin Glargine
- Where
- Argentina
- Volunteers
- 9 people
- Sponsor
- Sanofi
Type 1 Diabetes, Dawn Phenomenon
Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon
1. To investigate the effect of insulin glargine (Lantus™) vs NPH insulin regarding glycemic control during the early AM (dawn phenomenon) in individuals with type 1 diabetes. 2.
- Trial name
- DAWN (NCT00694122)
- Testing
- Lantus (glargine)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Massachusetts General Hospital
Type 2 Diabetes Mellitus
A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)
The purpose of this study is to test the effect MK-0941 as add-on therapy for adults taking insulin for Type 2 Diabetes.
- Trial name
- NCT00824616
- Testing
- MK-0941, Insulin
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 1
A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements
This study will look into how a base dose of insulin peglispro and insulin glargine will affect the meal time dose and efficacy of insulin lispro in type 1 diabetics.
- Trial name
- NCT02152384
- Testing
- Insulin Peglispro, Insulin Lispro, Insulin Glargine
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Diabetes in Pregnancy, Gestational Diabetes
Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)
The goal of this clinical trial is to see if diabetes in pregnancy can be treated with once daily dosing of insulin instead of once daily dosing plus insulin with meals. The main question this study aims to answer is: 1.
- Trial name
- SUGAR (NCT07171684)
- Testing
- Insulin glargine alone, Insulin glargine + insulin lispro
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- Rutgers, The State University of New Jersey
Type 1 Diabetes
To Evaluate add-on Effect of Nisha-Amalaki Tablets Along With Insulin on Glycemic Control in Type 1 Diabetes Patients (RCTNA)
Type-I diabetes mellitus (T1DM) is an autoimmune condition, in which the pancreas reduces/stops insulin production. Patients with T DM have to take insulin injections with every meal and also usually a long-acting preparation.
- Trial name
- NCT06487598
- Testing
- inj insulin to one group, Inj Insulin with Tab Nisha-Amalaki 500 mg twice a day
- Where
- India
- Volunteers
- 70 people
- Sponsor
- Hirabai Cowasji Jehangir Medical Research Institute